The combination of multiple imaging and neurochemical biomarkers, including PET imaging, MRI midbrain-to-pons area ratio (M:P), and CSF neurofilament light (NfL) levels, significantly improved the accuracy of diagnosis and differentiation of PSP from other neurodegenerative syndromes [102]. This evidence concerns the gene NEFL and supranuclear palsy, progressive, 1.